Drug recall · February 13, 2013
Taztia XT recall
Why: Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.
- Lots / codes
Lot #: 512146A, Exp 01/31/2014
- Quantity
- 3,040 bottles
- Company
- Watson Pharmaceuticals, Parsippany, NJ
- Distribution
- Nationwide and Puerto Rico
- Initiated
- December 18, 2012 · Voluntary: Firm initiated
- Classified
- February 4, 2013
- Reported
- February 13, 2013
- Ended
- July 30, 2014
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Diltiazem
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.